Literature DB >> 10027004

Rearrangements of RET and NTRK1 tyrosine kinase receptors in papillary thyroid carcinomas.

M A Pierotti1, P Vigneri, I Bongarzone.   

Abstract

A combined cytogenetic and molecular analysis of thyroid tumours has indicated that these neoplasms might represent a significant model for analysing human epithelial cell multi-step cancerogenesis. Thyroid tumours comprise a broad spectrum of lesions with different phenotypes and variable biological and clinical behaviour. Molecular analysis has detected specific genetic alterations in these different tumour types. In particular, the well-differentiated carcinomas of the papillary type are characterised by the activation of the tyrosine kinase receptors (TKRs) RET and NTRK1 proto-oncogenes. Cytogenetic analysis of these tumours has contributed to defining the chromosomal mechanisms leading to the TKRs' oncogenic activation. The results have shown that, in the majority of the cases, intra-chromosomal inversions of chromosome 10 and of chromosome 1 lead to the formation of RET-derived and NTRK1-derived oncogenes, respectively. Exposure to ionizing radiation is associated with papillary carcinomas, and RET activation has been suggested to be related to this event. All these findings are contributing to the definition of genetic and environmental factors relevant to the pathogenesis of thyroid tumours. Moreover, the molecular characterisation of specific genetic lesions could provide significant information about the association between ionising radiation and RET oncogene activation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10027004     DOI: 10.1007/978-3-642-46870-4_15

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  9 in total

1.  Aberrant ALK tyrosine kinase signaling. Different cellular lineages, common oncogenic mechanisms.

Authors:  M Ladanyi
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  Impact of pathognomonic genetic alterations on the prognosis of papillary thyroid carcinoma. ESES vienna presentation.

Authors:  Thomas J Musholt; Sonja Schönefeld; Christina H Schwarz; Felix M Watzka; Petra B Musholt; Christian Fottner; Matthias M Weber; Erik Springer; Arno Schad
Journal:  Langenbecks Arch Surg       Date:  2010-07-18       Impact factor: 3.445

3.  Dissection of the RET/β-catenin interaction in the TPC1 thyroid cancer cell line.

Authors:  Carmen J Tartari; Carla Donadoni; Elisa Manieri; Luca Mologni; Pamela Della Mina; Antonello Villa; Carlo Gambacorti-Passerini
Journal:  Am J Cancer Res       Date:  2011-06-01       Impact factor: 6.166

4.  RET polymorphisms might be the risk factors for thyroid cancer.

Authors:  Rui-Xue Huang; Fei Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 5.  Trk receptor expression and inhibition in neuroblastomas.

Authors:  Garrett M Brodeur; Jane E Minturn; Ruth Ho; Anisha M Simpson; Radhika Iyer; Carly R Varela; Jennifer E Light; Venkatadri Kolla; Audrey E Evans
Journal:  Clin Cancer Res       Date:  2009-05-05       Impact factor: 12.531

Review 6.  The Pathogenetic Role of the HGF/c-Met System in Papillary Carcinoma of the Thyroid.

Authors:  Luigi Ruco; Stefania Scarpino
Journal:  Biomedicines       Date:  2014-10-24

7.  Mapping of melanoma modifier loci in RET transgenic mice.

Authors:  T A Dragani; B Peissel; N Zanesi; A Aloisi; Y Dai; M Kato; H Suzuki; I Nakashima
Journal:  Jpn J Cancer Res       Date:  2000-11

8.  Nerve growth factor in cancer cell death and survival.

Authors:  Niamh H Molloy; Danielle E Read; Adrienne M Gorman
Journal:  Cancers (Basel)       Date:  2011-02-01       Impact factor: 6.639

9.  Special role of JUN in papillary thyroid carcinoma based on bioinformatics analysis.

Authors:  Wenzheng Chen; Qingfeng Liu; Yunxia Lv; Debin Xu; Wanzhi Chen; Jichun Yu
Journal:  World J Surg Oncol       Date:  2017-07-03       Impact factor: 2.754

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.